HC Wainwright Reaffirms “Buy” Rating for Atossa Therapeutics (NASDAQ:ATOS)

Atossa Therapeutics (NASDAQ:ATOS)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They presently have a $7.00 target price on the stock.

Separately, Ascendiant Capital Markets lifted their target price on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research note on Monday, December 9th.

Atossa Therapeutics Trading Down 3.3 %

NASDAQ:ATOS opened at $0.72 on Wednesday. Atossa Therapeutics has a 12 month low of $0.66 and a 12 month high of $2.31. The firm’s 50 day moving average is $0.80 and its 200 day moving average is $1.11. The stock has a market capitalization of $91.05 million, a PE ratio of -3.29 and a beta of 1.20.

Atossa Therapeutics (NASDAQ:ATOS) last issued its earnings results on Tuesday, March 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.01. Research analysts predict that Atossa Therapeutics will post -0.22 earnings per share for the current year.

Hedge Funds Weigh In On Atossa Therapeutics

A number of institutional investors have recently made changes to their positions in ATOS. Geode Capital Management LLC increased its stake in Atossa Therapeutics by 1.6% in the third quarter. Geode Capital Management LLC now owns 2,814,446 shares of the company’s stock valued at $4,278,000 after acquiring an additional 44,762 shares during the last quarter. State Street Corp lifted its stake in Atossa Therapeutics by 4.2% during the third quarter. State Street Corp now owns 1,732,221 shares of the company’s stock worth $2,633,000 after purchasing an additional 69,180 shares during the last quarter. Renaissance Technologies LLC boosted its holdings in shares of Atossa Therapeutics by 18.9% in the 4th quarter. Renaissance Technologies LLC now owns 1,557,632 shares of the company’s stock worth $1,471,000 after purchasing an additional 247,562 shares in the last quarter. Northern Trust Corp increased its position in shares of Atossa Therapeutics by 7.5% during the 4th quarter. Northern Trust Corp now owns 1,025,724 shares of the company’s stock valued at $968,000 after purchasing an additional 71,525 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of Atossa Therapeutics by 141.4% during the 4th quarter. JPMorgan Chase & Co. now owns 361,296 shares of the company’s stock valued at $341,000 after buying an additional 211,654 shares in the last quarter. Institutional investors own 12.74% of the company’s stock.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.